174 related articles for article (PubMed ID: 32995478)
21. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
22. Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells.
Melen GJ; Franco-Luzón L; Ruano D; González-Murillo Á; Alfranca A; Casco F; Lassaletta Á; Alonso M; Madero L; Alemany R; García-Castro J; Ramírez M
Cancer Lett; 2016 Feb; 371(2):161-70. PubMed ID: 26655276
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic adenovirus characterization: activity and immune responses.
Gil-Hoyos R; Miguel-Camacho J; Alemany R
Methods Mol Biol; 2014; 1089():117-32. PubMed ID: 24132482
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C; Fueyo J
Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.
Taipale K; Tähtinen S; Havunen R; Koski A; Liikanen I; Pakarinen P; Koivisto-Korander R; Kankainen M; Joensuu T; Kanerva A; Hemminki A
Oncotarget; 2018 Jan; 9(5):6320-6335. PubMed ID: 29464075
[TBL] [Abstract][Full Text] [Related]
26. Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology.
Ramírez M; García-Castro J; Melen GJ; González-Murillo Á; Franco-Luzón L
Oncolytic Virother; 2015; 4():149-55. PubMed ID: 27512678
[TBL] [Abstract][Full Text] [Related]
27. Combination of Mesenchymal Stem Cell-Delivered Oncolytic Virus with Prodrug Activation Increases Efficacy and Safety of Colorectal Cancer Therapy.
Ho CT; Wu MH; Chen MJ; Lin SP; Yen YT; Hung SC
Biomedicines; 2021 May; 9(5):. PubMed ID: 34068264
[TBL] [Abstract][Full Text] [Related]
28. Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens.
Brachtlova T; van Beusechem VW
Cells; 2018 Nov; 7(12):. PubMed ID: 30477117
[TBL] [Abstract][Full Text] [Related]
29. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
Cheng T; Song Y; Zhang Y; Zhang C; Yin J; Chi Y; Zhou D
Oncotarget; 2017 Apr; 8(16):26871-26885. PubMed ID: 28460470
[TBL] [Abstract][Full Text] [Related]
30. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
Ranki T; Särkioja M; Hakkarainen T; von Smitten K; Kanerva A; Hemminki A
Int J Cancer; 2007 Jul; 121(1):165-74. PubMed ID: 17315187
[TBL] [Abstract][Full Text] [Related]
31. Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.
Hemminki O; Oksanen M; Taipale K; Liikanen I; Koski A; Joensuu T; Kanerva A; Hemminki A
Mol Ther Oncolytics; 2018 Jun; 9():41-50. PubMed ID: 29989063
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients.
Martín-Carrasco C; Delgado-Bonet P; Tomeo-Martín BD; Pastor J; de la Riva C; Palau-Concejo P; Del Castillo N; García-Castro J; Perisé-Barrios AJ
Vet Sci; 2022 Jun; 9(7):. PubMed ID: 35878344
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors.
Yoon AR; Rivera-Cruz C; Gimble JM; Yun CO; Figueiredo ML
Mol Ther Oncolytics; 2022 Jun; 25():78-97. PubMed ID: 35434272
[TBL] [Abstract][Full Text] [Related]
34. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic viruses: From bench to bedside with a focus on safety.
Buijs PR; Verhagen JH; van Eijck CH; van den Hoogen BG
Hum Vaccin Immunother; 2015; 11(7):1573-84. PubMed ID: 25996182
[TBL] [Abstract][Full Text] [Related]
36. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.
Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO
Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131
[TBL] [Abstract][Full Text] [Related]
38. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
40. A mathematical model of oncolytic virotherapy with time delay.
Wang ZZ; Guo ZM; Smith H
Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
